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Lymphocyte function-associated antigen 3 (LFA-3)' is a widely distributed cell
surface glycoprotein that is a ligand for the T lymphocyte CD2 glycoprotein (1-4).
This receptor-ligand pair is used in many intercellular adhesion interactions, in-
cludingbindingofcytolytic Tlymphocytes to target cells (3) and thymocytes to thymic
epithelial cells (4). Both CD2 and one form ofLFA-3 have membrane-spanningpoly-
peptide segments that anchor them to the membrane (5-7), while a distinct form
of LFA-3 is anchored to the membrane by aglycosylphosphatidylinositol (GPI)moiety
at its COOH terminus (7-9). Despite these hydrophobiccomponents, purified CD2
and LFA-3 can be manipulated in the absence of detergents and can be shown to
bind to cells expressing LFA-3 and CD2, respectively, in radioreceptorassays (10-12).
CD2 also mediates rosetting of human T lymphocytes with sheep and human erythro-
cytes; the sheep ligand for CD2, T11-target structure (TUTS), is a homologue of
LFA-3 and can also be used in soluble form to bind to CD2 on cells (13, 14).
In addition to mediating adhesion, early studies suggested that CD2 could deliver
activating signals (15, 16). Subsequently it was found that several distinct pairwise
combinations of CD2 mAbs that bind to different classes of epitopes could trigger
T lymphocyte proliferation and function (17-21). Hunig et al. (22) showed that sheep
erythrocytes bearing T11TS were strongly mitogenic in the presence of a single CD2
mAb. Tiefenthaler et al. (23) demonstrated that purified LFA-3 or TUTS synergize
with a submitogenic dose of a mitogenic CD2 mAb combination. In that study the
form of LFA-3 or T11TS used was not defined and neither LFA-3 nor T11TS could
stimulate T cells in combination with a single nonmitogenic CD2 mAb.
We have been interested in defining the physiochemical properties of LFA-3 im-
portant in stimulation ofT cell function. There are 40,000 CD2 molecules per resting
T cell (24) and 200,000 LFA-3 sites per B lymphoblast (10) . Hence, signalingatten-
dant upon interaction via these adhesion molecules might involve engagement of
ahigher number ofsurface receptors than required for signalingthrough many lym-
phokine/hormone receptors, on the order of 102 to 103 (25, 26). Furthermore, a mul-
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timeric form ofLFA-3 might be expected to be more potent than a monomeric form,
both due to its predicted ability to aggregate the CD2 receptor in the plane of the
membrane and due to increased avidity. In this study we have compared the hydro-
dynamic, cell-binding, and cell-activating properties of multimeric LFA-3 with an
intact membrane anchor (mLFA-3) and phosphatidylinositol-specific phospholipase
C (PIPLC)-released monomeric LFA-3 (sLFA-3). Binding to CD2 was assessed by
inhibition of adhesion and radioligand binding assays with the general finding that
multimeric mLFA-3 binds much more avidly to cell surfaces than monomeric sLFA-3.
Cell activation was assessed by proliferation and Cat+ mobilization assays, which
also indicated that mLFA-3 was much more active. Correlation of mLFA-3 binding
and activation suggests that occupation of 104 to 105 CD2 sites is required for Cat+
mobilization and proliferation. These results are consistent with C132-mediated ac-
tivation during adhesion where a significant proportion of CD2 sites are probably
occupied .
Materials and Methods
Cells.
￿
PBMC were isolated by dextran sedimentation and Ficoll-Hypaque (Sigma Chemical
Co., St. Louis, MO) density gradient centrifugation. Peripheral blood T lymphocytes (PBL-
T) were enriched by nylon wool (Polysciences, Inc., Warrington, PA) filtration and plastic
adherence. TheJurkat cell line was obtained from Dr. M. K. Ho (DuPont Co., Boston, MA).
Cells were maintained in RPMI 1640, 10% FCS (Gibco Laboratories, Grand Island, NY),
5 MM L-glutamine, 50 14g/ml gentamycin (complete media). JY B-lymphoblastoid cells and
Jurkat cells for LFA-3 and CD2 purification, respectively, were grown by the Massachusetts
Institute of Technology Cell Culture Center (Cambridge, MA).
MonoclonalAntibodies.
￿
The TS2/9 and TS2/18 IgGI mAbs bind to LFA-3 and CD2, respec-
tively (1). The 9-1 IgG3 (20), D66 IgG2b (18), CD2 .1 IgG1 (19), 9.6 IgG2a (24), and 35.1
IgG2a (24) bind to epitopes on CD2 that are distinct from TS2/18 by competitive binding
or mutational analysis (27). 9-1 was a gift of Bo Dupont, Memorial Sloan Kettering Cancer
Institute, New York, NY. D66 was a gift ofDr. Alain Bernard, Institut Gustave-Roussy, Villejuif,
France. mAb 9.6 was a gift of Dr. John Hansen, Fred Hutchinson Cancer Research Center,
Seattle, WA.
LFA-3 Purification.
￿
LFA-3 was purified from Triton X-100 lysates of human erythrocytes
(mLFA-3) (11) or JY B-lymphoblastoid cells (6), or from supernatants of PIPLC-treated
JY B-lymphoblastoid cells (sLFA-3) by immunoaffinity chromatography on TS2/9 mAb-
Sepharose CL-4B (Pharmacia Fine Chemicals, Piscataway, NJ). In the latter case, 50 g of
viableJY cells were washed with HBSS and treated with Bacillus thuringiensis PIPLC (a generous
gift of Dr. Martin Low, Columbia University, New York, NY) in a total volume of 100 ml
for 1 h at 37'C . The concentration of enzyme used could hydrolyze 300 nmol/min/ml of
[3H]phosphatidylinositol at pH 7 in the presence of 0.1% deoxycholate detergent (28). The
cells were pelleted at 1,000 g and cell debris was pelleted at 100,000 g for 1 h. Lysates or super-
natants containing LFA-3 were passed over the affinity column and the column was washed
(11). LFA-3 from erythrocytes was eluted from the immunoaffinity column at pH 3 in the
presence of 1% octylglucoside (OG) detergent. LFA-3 from PIPLC supernatants was eluted
at pH 3 in the absence of detergent; fractions containing LFA-3 were pooled (4-6 ml) and
passed over a 1-ml phenyl-Sepharose column (Pharmacia Fine Chemicals) equilibrated with
25 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 0.025% NaN3 (TSA). Some preparations were
passed over a 1-ml protein A-Sepharose CL-4B column after diluting 1 :1 with MAPS binding
buffer (with 1% OG for mLFA-3) (Bio-Rad Laboratories, Richmond, CA). Aggregated
mLFA-3 was prepared by three cycles ofultrafiltration using a Centricon 30 apparatus (Amicon
Corp., Danvers, MA), adding 2 ml ofPBS and reducing the volume to 50 i1 with each cycle.
Since the final ultrafiltrate ofthe last step contained the same low molecular weight compo-
nents as the final retentate but not any LFA-3, this ultrafiltrate was used as a control for effectsDUSTIN ET AL .
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of buffer components in subsequent experiments . SDS-PAGE and silver staining were done
by the procedures of Laemmli (29) and Morrissey et al . (30), respectively.
Sucrose Gradient Sedimentation and Gel Filtration .
￿
Linear 10-34% sucrose gradients in H 2O
or D20 were prepared in 2.5 x 0.5 inch polyallomer tubes . Samples (200 A1) containing 10
mg/ml of a standard protein and 150,000 cpm 1251-LFA-3 (see below) were layered on top
of the gradients, the gradients were centrifuged in a SW55Ti rotor at 44,000 rpm at 4°C
for 12 or 40 h, and they were decelerated without brake . Fractions were collected from the
top of the gradient (31) and assayed for absorbance at 280 nm, cpm, and refractive index .
The partial specific volume (v) and sedimentation coefficients were calculated by the method
of Clarke (32). Ovalbumin, BSA, bovine IgG, and thyroglobulin were used as standards for
calculating the average viscosities (32) . HPLC gel filtration was done using a DuPont GF-250
column equilibrated withPBS or PBS with 1% OG detergent . Standard proteins used were
ovalburnin, BSA, bovine IgG, and thyroglobulin which have diffusion coefficients (D x 10 7 )
of 7 .76, 6 .1, 4 .1, and 2.65 respectively (33) .
LFA-3 Iodination and Binding Assays .
￿
LFA-3 (3 or 6 t~g) was iodinated with 200 ACi of
Na1251 (New England Nuclear, Boston, MA) using 1,3,4,6-tetrachloro-3a,6a-diphenylglycou-
ril (Pierce Chemical Co., Rockford, IL) (34) . The iodinated LFA-3 in the presence of 1 mg/ml
BSA was dialyzed with a >95% recovery of LEA-3 . For binding assays Jurkat cells orPBLT
were washed and resuspended in complete media to 2 x 10 7 cell/ml . The cells were pretreated
with any reagent to be tested for blocking of LEA-3 binding for 30 min at 4°C . 1251-LFA-3
(30,000 cpm/ng) was added to give a final cell concentration of 107 cells/ml in 400 A,1 and
incubated an additional hour at 4°C . Three 100-Al aliquots from each binding mixture were
layered on top ofa 100-I .1 cushion ofa 2:1 mixture of dibutyl and dinonylphthalates in micro
sediment separation tubes (Sarstedt, Inc ., Princeton, NJ) and centrifuged parallel to the cen-
trifugal field at 10,000 g for 5 min . The tips containing the cells were cut off and counted .
In some binding experiments the indicated number of cells were incubated with 1251-mLFA-3
and mAb for 90 min at 4°C and washed three times with media over 15 min . These separa-
tion methods gave identical results with mLFA-3 .
Proliferation Assays.
￿
Proliferation ofPBMC orT lymphocytes was assayed by [ 3H]thymi-
dine incorporation . Assays were done in flat wells with 0.5 x 10 5 cells/well in 100 1.1 of com-
plete media with 20% FCS (HyClone Laboratories, Logan, UT) . After the indicated period
of time each well was pulsed with 1 ACi of [ 3H]thymidine (50-90 Ci/mmol, New England
Nuclear) for 16 h, after which the DNA was collected using a PhD cell harvester (Cambridge
Technology, Inc., Cambridge, MA) .
Intracellular Ca' Measurements with Indo-1 .
￿
Jurkat cells or PBLT were loaded by incuba-
tion with 8 AM Indo-1 AM (Molecular Probes, Junction City, OR) at 10 6 cells/ml in RPMI
1640 10% FCS at 37°C for 45 min . The cells were washed three times and kept at 20-24°C
until 10 min before each run, at which point the cells were raised to 37°C (35) . Indo-1 was
excited at 351-364 nm and emission was measured at 405-415 nm (violet) and 475-485 nm
(blue) on the Epics V flow cytometer (Coulter Electronics, Hialeah, FL) . The ratio between
the log channel number for violet/blue was used as an indication ofthe relative intracellular
Cat' level (indo-1 ratio in Figs. 4 and 5) . The maximal ratio was determined after addition
of 10 Ag/ml ionomycin (Calbiochem-Behring Corp ., La Jolla, CA) .
Results
Purification of PIPLC-released LFA-3.
￿
LFA-3 released from the surface of B-lym-
phoblastoid cells by PIPLC (sLFA-3) was purified by immunoaffinity chromatog-
raphy (not shown) . The appearance ofthe LFA-3 forms by SDS-PAGE was identical
to material previously purified fromJY cells (6), except that peptide:N glycosidase
treatment yielded a single band of 25,500 rather than two bands of25,000 and 29,000
(not shown) . The possibility of contamination by LFA-3 with an intact membrane
anchor(mLFA-3) was reduced by passing the immunoaffinity purified material over
a phenyl-Sepharose column . The sLFA-3 had biological activity based on its ability506
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FIGURE 1.
￿
Inhibition of E rosetting by sLFA-3 and
mLFA-3. Sheep erythrocytes (106) and Jurkat cells
(104) were mixed in a final volume of 20 pl of RPMI
1640 with 10% FCSwith sLFA-3 (A) or mLFA-3 (p)
and incubated 30 min at 4°C. The cells were pelleted
at 50 g for 5 min and left at 4°C for an additional
1 h. The pellets were gently resuspended and rosettes
enumerated (200 Jurkat cells counted). The asterisk
near some points indicates aggregation ofJurkat cells.
Averaged results of two experiments are shown.
to inhibit sheep erythrocyte binding to Jurkat cells in a 1-h assay at 4°C (Fig. 1).
Maximal inhibition of rosetting by sLFA-3 was obtained at 2.6 JM and was not ac-
companied by the agglutination of Jurkat cells as seen when mLFA-3 was used in
parallel and as previously described (11). Maximal inhibition with mLFA-3 was ob-
tained at between 2.5 and 25 nM.
Hydrodynamic Properties ofLFA-3 Forms.
￿
Gelfiltration results suggested that mLFA-3
formed large, homogeneous aggregates in the absence of detergent based on com-
parisonto sLFA-3 andprotein standards. To determinehow many LFA-3 monomers
were presentin sLFA-3 andmLFA-3 their molecularmass was determined. The par-
tial specific volume and sedimentation coefficient of sLFA-3 were determined by su-
crose gradient sedimentation in H2O and D20. These values and diffusion coeffi-
cient determined by gel filtration were used to calculate the molecular mass (Table
1). The molecular mass ofsLFA-3 was 80,000, which is consistent with a single highly
glycosylated polypeptide chain and is in good agreement with the molecular mass
of 70,000 from SDS-PAGE (1, 11). The molecular mass of mLFA-3 in the presence
and absence of detergent was determined from the sedimentation coefficient on
H2O sucrose gradients, the diffusion coefficient from gel filtration, and the partial
specific volume of sLFA-3 adjusted for addition of diacylglycerol with or without
an OG micelle associated. Molecular masses of 73 and 540 kD were determined
in the presence and absence of OG, respectively, suggesting that in OG LFA-3 is
a monomer, and afterremoval ofOG the mLFA-3 micelleis an octamer. ThemLFA-3
TABLE I
Hydrodynamic Properties of LFA-3 Forms
Iodinated LFA-3 forms were sedimented on 10-34% sucrose gradients in H2O
or D20 . Centrifugation was for 40 h (sLFA-3) or 12 h (mLFA-3). Diffusion
coefficients were estimated from gel filtration.
* Calculated from v for sLFA-3 using for diacylglycerol v = 1 .18, and for OG
a micelle size of 8 kD (not subracted above) and v = 0.91 .
LFA-3 form v s20-- D M,
m11g x 1013 x 107
sLFA-3 0.725 3 .66 4.1 80,000
mLFA-3 with OG 0.743* 3 .12 4.1 73,000
mLFA-3 0.730* 12 .3 2.5 540,000J
1 2 3 4 5 6 7 6 910111213141516
traction
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micelles were relatively homogeneous in comparison to glycoprotein standards and
detergent solubilized mLFA-3 by sedimentation (Fig. 2)and gel filtration (not shown) .
Binding ofLFA-3 Micelles to Cell Surface CD2 at 4 and 37°C. Previously, we had
shown that iodinated LFA-3 binds to CD2+ cells when Triton X-100 is absorbed
with 15% BSA and that this binding is inhibited by CD2 mAb and LFA-3 mAb
(11) ; however, the aggregation state and dissociation constant were not determined .
We compared the cell-binding properties of the mLFA-3 octamer with the sLFA-3
monomer . While mLFA-3 from erythrocytes orJY cellsbound specifically to Jurkat
T leukemic cells or resting PBLT, sLFA-3 bindingwas virtually undetectable when
using sLFA-3 at 4nM (Table II). Scatchardanalysis showed that erythrocyte mLFA-
3 boundwith a dissociation constant of 1.5 nM with 420,000 LFA-3 moleculesbound
perJurkat cell and 12 nM with 65,000 LFA-3 molecules bound per resting T cell
at 4°C (Fig. 3) . Bindingof sLFA-3 under saturating conditions was not undertaken
dueto the relatively large amounts of material that would be required . The amount
ofsLFA-3 binding in Table II suggests that the Kd for binding to cell surface CD2
is
￿
400 nM . Consistent with this estimate, the Ki for inhibition of rosetting was
400 nM (Fig . 1).
Dissociation ofmLFA-3 from the surface ofJurkat cells occurred very slowly with
a t1/2 >600 min. In the presence of 10 or 100 ug/ml TS2/18 mAb, the dissociation
rates had t1/2 of 60 and 2 min, respectively (not shown) . Since TS2/18 mAb and
mLFA-3 appear to bind CD2 in acompetitive manner, the increased rate of dissoci-
TABLE II
Binding of PIPLC-released LFA-3 to Jurkat
FIGURE 2 .
￿
Sucrose gradient sedimentation
ofmLFA-3 in the presence andabsence ofde-
tergent . 125I-erythrocyte mLFA-3 (150,000
cpm) was sedimented for 20 h on linear
10-34% sucrose gradients in H2O with no
detergent ([]) or 1% OG (0). Standards
(-----) were ovalbumin (s20,w = 3.55), bo-
vine IgG (6.92), and thyroglobulin (19.2),
whichwere runwithout detergent . Fractions
were collected from the top of each gradient
(1 = top) .
Jurkat cells (106) were incubated with 200,000cpm (4 nM final) of either sLFA-3
or mLFA-3, both prepared fromJY cells, for 2 h at 4°Cand aliquots were cen-
trifuged through oil cushions . mLFA-3 was prepared from JY cells to avoid differ-
ences in glycosylation that would complicate the interpretation of the results .
Similar results were obtained with erythrocyte mLFA-3 .
Bound LFA-3
Additions sLFA-3 mLFA-3
CPm
control mAb 5,553 t 387 148,760 f 4,003
TS2/18 4,030 t 14 5,023 t 23508
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Equilibrium binding ofmLFA-3 toJurkat cells
and resting T cells. (A) Binding of mLFA-3 was for 1 h at
0.5
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4°C in the presence ofcontrol mAb(0, E) or TS2/18 mAb
(A, A) to 5 x 104 Jurkat cells (filled symbols) or 5 x 105
Input (CPM x 10e)
￿
nylon wool-enriched T cells (open symbols). The specific ac-
tivity of mLFA-3 was not the same for Jurkat and PBLT.
Bound and free were separated by three washes with cold
media. (B) The data were analyzed by the method of
Scatchard after subtracting the binding in the presence of
TS2/18 mAb.
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ation in the presence ofCD2 mAb suggests that mLFA-3 bindsmultivalentlyto cell
surface CD2. Complete reversal of mLFA-3 binding by CD2 mAb demonstrated
that LFA-3 is not endocytosed after 90 min at 4°C and that it was not inserted into
membranes through its phosphatidylinositol glycan anchor during this period (9).
However, mLFA-3 did appear to become internalized whenJurkat cellsor PBLwere
elevated to 37°C, since 30-40°Jo of cell-associated counts could not be dissociated
by TS2/18 mAb after 30 min at 37°C (Table III).
We screened for CD2 mAbs that would not block binding of mLFA-3 to Jurkat
cells or peripheral T cells. CD2 mAbs that inhibit rosetting were able to completely
TABLE III
Accessibility of Bound mLFA-3 to Extracellular TS2118
Jurkat cells or PBL-T (5 x 105) were incubated with 1251-mLFA-3 (100,000
cpm) for 60 min at 4°C or 30 min at 37°C. Jurkat cell and PBL-T CD2 was
initially at ti10% occupation with LFA-3. The postincubation at 4°C without
or with TS2/18 was carried out for 6 h to insure complete dissociation of accessi-
ble LFA-3 . Data are means of quadruplicate determinations with standard devi-
ations.
Additions Cell-associated mLFA-3
Preincubation Postincubation Jurkat PBL-T
cpm
4°C Control Control 11,441 ± 500 1,543 ± 225
TS2/18 Control 86 + 5 95 + 14
Control TS2/18 299 ± 26 111 t 13
37°C Control Control 10,990 ± 941 1,326 t 86
TS2/18 Control 67 f 12 89 ± 19
Control TS2/18 4,975 t 400 390 ± 43DUSTIN ET AL .
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TABLE IV
Inhibition of mLFA-3 Binding by CD2 mAb
Binding toJurkat cells was done for 1 h at 4°C . Input counts were 100,000/106
cells . Antibodies were used at saturation as determined by flow cytometry . Bound
and free were separated by centrifugation through a 15% BSA cushion . All the
mAbs except control andOKT3 are against CD2 . Results are averages ofquad-
ruplicates with standard deviation and are representative of two experiments .
block mLFA-3 binding: TS2/18, 9.6, 9-2, CD2 .8, andCD2.9 (Table IV). The one
exception to this wasD66mAb, which blocks all but the most stable E rosettes (36),
but only blocked binding of mLFA-3 by 24% . This may be a function of low D66
epitope expression (36) . The 35 .1 mAb also blocked mLFA-3 binding partially (67%) .
The 9-1 and CD2.1 mAb, which do not inhibit rosetting, did not have any effect
on mLFA-3 binding .
Effect ofLFA-3 Forms on Intracellular Free Ca" .
￿
Several studies have shown that
combinations of CD2 mAbs can stimulate Cat' fluxes in T cell tumor lines (37,
38) and resting PBLT (39, 40) . We have examined Cat+ mobilization stimulated
by LFA-3 together with CD2 mAbs that do not block LFA-3 binding . Using a flow
cytometer [Ca2+ ]i responses can be measured within minutes and the monodis-
persed or aggregated nature of the cells can be simultaneously evaluated, making
it possible to determine whether the binding of mLFA-3 aggregates to cell surface
CD2 leads to an activation signal without promoting cell-cell interaction by inserting
into membranes or crosslinkingCD2 molecules from different cells . When mLFA-3
(up to 240 nM) was added to Jurkat cells there was no change in the Indo-1 ratio
within 15 min (not shown) . Similarly, CD2.1 mAb (67 nM) alone had no effect on
[Ca2+] ; (not shown) . However, when mLFA-3 andCD2.1 mAbs were added simul-
taneously there was a rapid increase in [Ca2l ] ; (Fig. 4 A), which was similar in mag-
nitude andmore sustained than that seen with CD3 mAb (Fig . 4 C) . The combina-
tion ofmLFA-3 and 9-1 did not stimulate a Cat+ flux . The combination of sLFA-3
(40-800 nM) with CD2 .1 did not result in an increase in [Ca2 + ] ; in Jurkat, while
subsequent addition ofmLFA-3 to the same sample resulted in a rapid increase in
[Ca2l ] ; (Fig . 4 B) . There was no evidence of cell-cell interaction during these ex-
periments since there was no change in light scatter (not shown) .
To allow direct comparison ofCat+ mobilization to equilibrium mLFA-3 binding
data, Jurkat cells were equilibrated with different concentrations ofmLFA-3 by in-
mAb 12,91-mLFA-3 bound/106 cells
c¢m
Control mAb 20,531 t 596
9.6 173 ± 17
TS2/18 153 f 57
9-2 154 t 8
CD2.8 173 t 29
35 .1 7,171 t 98
CD2.9 164 t 50
CD2 .1 22,817 ± 362
9-1 24,092 t 878
D66 16,073 t 72
OKT3 21,342 t 487510
￿
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FIGURE 4 .
￿
Cytoplasmic Ca t' mobilization in Jurkat cells induced by CD2.1 and mLFA-3 or
sLFA-3 . Indo-1 loaded Jurkat cells were treated with: (A) mLFA-3 (40 nM) and CD2 .1 (1:500
ascites); (B) sLFA-3 (400 nM) andCD2 .1 followed by mLFA-3 (40 nM) or (C) OKT3 (1 :10 cul-
ture supernatant) . Reagents were added at 1 min (gap in data collection) and (B) at 1 minand 5min .
cubation for 30 min at 37°C, then CD2 .1 mAb was added to initiate Ca2+ mobili-
zation (Fig. 5) . Under these conditions, an approximately half-maximal increase
in [Ca2+] ; was seen at -1.2 nM mLFA-3, which is very close to the Kd for mLFA-3
binding to Jurkat CD2 determined above . Therefore, it appears that the signal de-
livered through CD2 by mLFA-3 and CD2 .1 that leads to an increase in [Ca2+ ];
is proportional to the occupation ofCD2 with mLFA-3 andCD2.1 mAb up to satu-
ration . Addition of ionomycin to Jurkat after 240nM mLFA-3 and CD2.1 resulted
FIGURE 5 .
￿
Concentration dependence ofJurkat [Ca2' ] ; increase on mLFA-3 occupation ofCD2.
Jurkat cells were incubated with the indicated concentration of LFA-3 for 30 min at 37°C . CD2.1
(1:500 ascites) wasadded after a30-60-s data collection on flow cytometer. Thebottom ofthe figure
shows histograms ofsections through activation time plots at 3min : 0.04nM (- ), 0.4 nM (---),
1.2 nM (- -), 4 nM (---) and 40 nM ( . ..) .DUSTIN ET AL.
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TABLE V
Induction of T Cell Proliferation by mLFA-3 and CD2.1
Additions were as indicated on day zero: rIL-2 (0.1 ng/ml), PMA (1 nM), CD2 .1
(1:500 dilution of ascites or 10 kg/ml), and mLFA-3 (40 nM). Concentrations
of sLFA-3 were 800 nM in Exps . 1 and 3 and 40 nM in Exp. 2. PHA (1 14g/ml)
gave 80,000-100,000 cpm on day 3 to 4 in these experiments. Wells were
pulsed with [3H]thymidine on day 3 for 16 h. Results are means of triplicates
and are representative of 14 experiments.
in a further increase in [Ca2 +]i suggesting that the Indo-1 was not at saturation for
Ca2+ in these experiments (not shown). Similar results were obtained when mLFA-3
and CD2.1 were added simultaneously except the kinetics of the responses at lower
LFA-3 concentrations were slower (not shown).
Mitogenic Effects of LFA-3 Forms on Resting T Cells.
￿
It has been shown that the ag-
gregated form of mLFA-3 alone had no effect on PBLT proliferation, but can in-
duce proliferation of PBLT in the presence of submitogenic concentrations of T112
and T113 CD2 mAb, but not with either T112 or T113 separately (23). We evaluated
the ability of the CD2.1 and 9-1 mAb to induce proliferation with mLFA-3 micelles.
The combination of mLFA-3 (40 nM) with the CD2.1 mAb was strongly mitogenic
for PBMC from all donors tested (Table V), while mLFA-3 and 9-1 was weakly mito-
genic or nonmitogenic (not shown). The mitogenic response to mLFA-3 and CD2.1
was usually (9 of 10 donors) seen in the absence of exogenous IL-2, even in donors
for which CD2.1 mAb with CD2 .9 mAb required exogenous IL-2 (see reference
19), although submitogenic PMA increased the response. Stimulation ofDNA syn-
thesis by mLFA-3 and CD2 .1 mAb peaked on days 3-4; a pulse on day 3 was used
for all experiments (not shown). In the presence of exogenously added IL-2 and 1
nM PMA, the optimal periods were days 3-4 and days 4-5, respectively. The combi-
nation of sLFA-3 between 40 and 800 nM and CD2.1 mAb with or without PMA
was not mitogenic for PBMC in two ofthreeexperiments for which sufficient amount
of material could be obtained (Table V). In one experiment a weak response was
seen with sLFA-3, CD2.1, and PMA. Experiments with the same donors showed
strong responses to mLFA-3 plus CD2.1 mAb with or without PMA.
Additions
3H-thymidine
Exp. 1
incorporation/5 x
Exp. 2
cpm
104 PBMC
Exp. 3
buffer 593 392 417
mLFA-3 411 645 549
CD2.1 437 839 646
IL-2 1,451 2,145 1,034
mLFA-3 + IL-2 1,345 1,399 1,284
CD2.1 + IL-2 1,609 2,039 1,545
PMA 1,713 1,382 834
mLFA-3 + PMA 1,549 978 828
CD2.1 + PMA 1,704 1,252 1,009
mLFA-3 + CD2.1 22,294 35,439 47,478
mLFA-3 + CD2.1 + IL-2 22,497 37,065 45,384
mLFA-3 + CD2.1 + PMA 77,784 114,313 153,240
sLFA-3 + CD2.1 768 - 755
sLFA + CD2 .1 + PMA 926 1,156 33,535
mLFA-3 + CD2.1 + sLFA-3 23,172 - -512
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FIGURE 6.
￿
Dose-response for LFA-3 andCD2 .1 induced
proliferation. PBMC (5 x 104) were treated with the in-
dicated concentration of rnLFA-3 with no addition (1]),
PMA (1 nM) (/), CD2.1 (10 hg/ml) (" ), or CD2.1 and
PMA (O). Wells were pulsed on day 3 for 16 h.
The dose-responses for mLFA-3 and CD2.1 mAb were determined in the pres-
ence of saturating concentrations of the other reagent. In the presence of saturating
CD2.1 mAb (67 nM) maximal PBMC or PBL-T proliferation was obtained with
4 nM mLFA-3 (Fig. 6) . This is below the Ki for mLFA-3 binding to PBLT of 12
nM . The CD2 .1 mAb did not affect the K~, for "'I-mLFA-3 binding to resting T
cells at 4°C (not shown) . The presence of exogenous IL-2 did not alter the dose-
response ; however, addition of 1 nM PMA decreased the mLFA-3 concentration
required for maximal response 10-fold. Similarly, in the presence of excess (40 nM)
mLFA-3, the CD2.1 mAb concentration giving a maximal response was 6.7 nM alone,
but 0.67 nM in the presence of 1 nM PMA (not shown).
Discussion
We have compared the ability of soluble LFA-3 micelles and monomers to bind
to CD2 expressing cells and stimulate T lymphocyte activation. Hydrodynamic anal-
ysis by gel filtration and sucrose gradient sedimentation suggests that PIPLC-released
sLFA-3 is a single polypeptide chain in solution and thus interacts with CD2 monova-
lently. LFA-3 with an intact membrane anchor forms protein micelles ofeight mono-
mers. The formation of homogeneous micelles by GPI-anchored proteins such as
Thy-1 has been observed previously; the LFA-3 micelles contain fewer monomers
than for Thy-1, which forms micelles of 16 monomers (41). The effect of CD2 mAb
on dissociation rates suggests that LFA-3 micelles bind multivalently, this accounts
for the 2-3-log difference in avidity between LFA-3 micelles and monomers. The
dissociation constant for mLFA-3 binding to cell surface CD2 was determined to
be in the 10 - ' to 10- R M range. The 5-10-fold higher avidity of mLFA-3 for binding
to Jurkat cells than to resting T cells might be due to different CD2 densities giving
rise to differences in the number of CD2/LFA-3 interactions; alternatively, differ-
ences in surface charge or the glycocalyx may be important. A low affinity and rapid
dissociation rate for single CD2/LFA-3 interactions is consistent with the rapidly
reversible adhesion demonstrated by cytolytic T cells.
Jurkat cells and resting T cellshave -200,000 and -40,000 CD2 antibody binding
sitesper cell, respectively (24, 42). Saturation binding showed that 420,000 and 65,000
mLFA-3 monomers (in octameric micelles) bind toJurkat and resting T cells, respec-
tively. Comparison of these numbers suggest that mLFA-3 micelles bound to Jurkat
with an average of four LFA-3 sites per octamer and to resting T cells with an av-
erageoffive sites per octamer. This would explain the ability of mLFA-3 to agglutinate
Jurkat cells (11), since four mLFA-3 molecules per micelle would be available for
binding to CD2 on another cell. The dissociation constant for monovalent interac-DUSTIN ET AL.
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tion of sLFA-3 with CD2 is suggested to be in the range of 10-7 to 10-6 M, based
on the amount of binding obtained in assays with a single sLFA-3 concentration
and the inhibition of sheep erythrocyte rosetting by sLFA-3.
After incubation at 37°C, some specifically bound LFA-3 micelles were not released
from the cell by CD2 mAb in the media, suggesting receptor-mediated endocytosis
of soluble phase mLFA-3. It is not clear whether this has any implication for CD2
function in adhesion or activation. Erythrocyte-T cell rosettes are more stable at
4°C than at 37°C (43), and it is possible that active rearrangement of ligated CD2
by a mechanism shared with the process of receptor-mediated endocytosis might
be responsible for weakening adhesion.
The combination of mLFA-3 and CD2.1 mAb stimulated a rapid rise in [Ca
2+];
in Jurkat cells and resting T cells and induced proliferation of PBL. This system
has advantages over the previously described system in which LFA-3 micelles were
found to synergize with submitogenic doses of two CD2 mAbs (23). The use of a
single CD2 mAb that has no mitogenic effects on its own is less complicated and
allowed titration of each reagent when the other was kept at saturation.
Ca
2+ mobilization in Jurkat was proportional to predicted occupation of CD2
by mLFA-3, with maximal stimulation occurring when -400,000 mLFA-3 mole-
cules (-50,000 micelles) were bound to the Jurkat cell at saturating concentrations
of CD2.1 mAbs. The relative increase in [Ca2+ ]; was less dramatic in resting T cells
(data not shown), consistent with these cells having one fifth the number of CD2
molecules as Jurkat (24, 42). These results suggest that -104 to 105 CD2 molecules
must be occupied by LFA-3 and CD2.1 to stimulate an increase in [Ca2+] .
In proliferation experiments the concentration of mLFA-3 required for a max-
imal response in the presence of saturating CD2.1 was just below the Kd for mLFA-3
binding. In contrast to the Ca2+ mobilization assay the stimulus in the prolifera-
tion assay is applied over a longer period of time and may be cumulative; further-
more, the function ofaccessory cells may increase the sensitivity ofthe T cells. Addi-
tionally, the properties ofthe T cellscan change during culture and the actual avidity
for mLFA-3 binding may have increased. The addition of submitogenic PMA de-
creased the amount of LFA-3 required to obtain a proliferative response 10-fold.
The presence of phorbol esters has been shown to complement single CD2 mAbs
and antibody pairs (19, 21) and may eliminate the requirement for a substantial in-
crease in [Ca2+]; (21).
These results suggest that CD2 is relatively inefficient in producing its effect com-
pared with hormone receptors that are frequently effective in producing biological
responses when 102 to 103 sites are occupied per cell (26, 27). The requirement for
occupation of -104 to 105 CD2 sites by LFA-3 for maximal response is consistent
with signaling through CD2 during adhesion. The LFA-3 density on many cell types
makes occupation ofthis number of CD2 molecules by LFA-3 plausible during cell-cell
interactions.
In proliferation and Ca
2+ mobilization experiments sLFA-3 and CD2 .1 had no
or marginal effect. It is not plausible to conclude that the sLFA-3 is intrinsically
inactive in activating T cells since the degree of CD2 occupation may not have been
sufficient at the sLFA-3 concentrations available. Larger (mg or greater) quantities
of sLFA-3, probably generated by overexpression of cloned LFA-3, will be necessary
to more accurately determine the affinity of monomeric CD2/LFA-3 interactions
and to further evaluate the activating potential of monomeric LFA-3 .514
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While mLFA-3 and CD2.1 were a potent mitogen for T cells, the combination
of mLFA-3 and 9-1 was virtually inactive for stimulating proliferation in PBMC cul-
tures and in Jurkat Ca21 mobilization assays. Subsequent to our observations, it
has been found that 9-1 and mLFA-3 are mitogenic for thymocytes, although not
as strongly as CD2.1 and mLFA-3 (44). In contrast to the requirements of mature
T cells, exogenous IL-2 or a second mAb to CD28 are requisite for proliferation
in the thymocyte system (44). LFA-3 on the surface of sheep erythrocytes can stimu-
late human CD2 transfected murine T cell hybridomas in conjunction with 9-1 (45).
However, sheep erythrocytes may present LFA-3 differently or supply other signals
so these results are not directly comparable to ours. Mutational analysis indicates
that CD2 .1 is similar to 9-1 in that both fail to react or react weakly with a double
substitution in the second Ig-like domain and a single substitution, 149Q, in the
first domain (Peterson, A., and B. Seed, personal communication). However, CD2 .1
binds to more sites on resting T cells than 9-1, suggesting that its interaction with
CD2 differs in some way.
The natural counterpart of the CD2.1 mAb in T cell activation is not known. There
may be another cell surface ligand or a soluble ligand for CD2 that binds to a different
site on CD2 than LFA-3 and allows activation to occur in the absence of specific
antigen. The 9-1 mAb and certain CD3 mAbs can synergize to stimulate T cell prolifer-
ation (46). Furthermore, the CD3 mAb increases expression of the 9-1 epitope on
resting T cells at 4°C, suggesting a physical interaction between CD2 and CD3 in
the plane of the membrane (46). Therefore, LFA-3-ligated CD2 may cooperate with
the CD3Ti complex in antigen-specific activation. In one scenario, the ligated an-
tigen receptor-CD3 complex may contact CD2 at the CD2.1 epitope. In this case,
CD2 would not offer an alternative, antigen-independent pathway of T cell activa-
tion but might synergize with the antigen-specific pathway to amplify the signal from
a small number of T cell receptor-ligand interactions .
Summary
LFA-3 was purified with an intact (mLFA-3) or an enzymatically removed mem-
brane-anchoring domain (sLFA-3). Gel filtration and sucrose gradient sedimenta-
tion showed sLFA-3 to be a single highly glycosylated polypeptide chain in solution,
while mLFA-3 formed micelles of 8 LFA-3 monomers. '2'I-mLFA-3 bound to Jurkat
T leukemic cell surface CD2 with much higher avidity than sLFA-3 . mLFA-3 binding
had characteristics of a multivalent interaction with cell surface CD2 and had an
avidity of 1 .5 nM for Jurkat cells and 12 nM for resting T cells. Two CD2 mAbs
tested did not block mLFA-3 binding: 9-1 and CD2 .1. These mAbs were tested in
combination with LFA-3 for their ability to activate T cells. The combination of
mLFA-3 and CD2.1 mAbs induced a rapid increase in cytosolic free Ca
2+ in Jurkat
cells which was proportional to mLFA-3 occupation of CD2 sites. sLFA-3 showed
no activity in the Ca2+ flux assay. The combination of mLFA-3 and the CD2.1
mAbs significantly stimulated proliferation ofPBMC . The combination of mLFA-3
and 9-1 mAbs was weakly or not mitogenic for the same cells. The combination of
CD2.1 and sLFA-3 at concentrations up to 480 nM was not consistently mitogenic.
Therefore, monomeric LFA-3/CD2 interaction appears to have a relatively low affinity,
while multimeric LFA-3 binds with high avidity. T cell activation by binding ofLFA-3DUSTIN ET AL .
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to CD2 appears to require occupation of 104 to 10 5 CD2 sites, which is likely to
occur during adhesion, but is rare in receptor systems with soluble ligands .
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